AstraZeneca, Hutchmed's Orpathys included in China's national reimbursement drug list
Golden_Brown

Hutchmed (China) (NASDAQ:HCM) said on Wednesday that Orpathys (savolitinib) was included in the updated National Reimbursement Drug List (NRDL) in China to treat certain patients with a type of non-small cell lung cancer (NSCLC).
The company noted that after negotiations with China's National Healthcare Security Administration (NHSA), Orpathys was added to the list for treating adult patients with locally advanced or metastatic NSCLC with MET exon 14-skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy.
The updated NRDL will be effective March 1.
Savolitinib, marketed in China as Orpathys, is an oral, selective MET tyrosine kinase inhibitor (TKI) jointly developed by AstraZeneca (NASDAQ:AZN) and Hutchmed.
Hutchmed noted that it takes the lead for the drug in China, while it it is commercialized by AstraZeneca worldwide.
"The NRDL has significantly broadened access to novel medicines for Chinese patients. We are gratified to see that our third novel oncology medicine, ORPATHYS, will be included in this yearâs NRDL update," said Hutchmed's CEO and Chief Scientific Officer Weiguo Su.
Orpathys was approved in China in June 21 to treat certain patients with NSCLC with MET exon 14 skipping alterations.